Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand

Blood

Volumn 118, Issue 14, 2011, Pages 3811-3817

  Jain, Ashish ^a   Kovacs, Joseph A ^b   Nelson, David L ^c   Migueles, Stephen A ^a   Pittaluga, Stefania ^c   Fanslow, William ^d   Fan, Xiying ^a   Wong, Duane W ^e   Massey, Justin ^a   Hornung, Ronald ^f   Brown, Margaret R ^b   Spinner, Jacob J ^a   Liu, Shuying ^a   Davey, Victoria ^a   Hill, Harry A ^g   Ochs, Hans ^h   Fleisher, Thomas A ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d AMGEN INC   (United States)

^e Arizona Allergy Associates   (United States)

^f SAIC FREDERICK INC   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD40 LIGAND; CD45RA ANTIGEN; CD45RO ANTIGEN; COTRIMOXAZOLE; FLUCONAZOLE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; RECOMBINANT CD40 LIGAND; RECOMBINANT CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; B LYMPHOCYTE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; COCCIDIOIDOMYCOSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPER IGM SYNDROME; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INJECTION SITE INFECTION; KNOCKOUT MOUSE; LYMPH NODE; MAINTENANCE THERAPY; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SIDE EFFECT; SKIN INFECTION; SUBSTITUTION THERAPY; SURVIVAL; SYSTEMIC MYCOSIS; TH1 CELL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; X CHROMOSOME LINKED DISORDER; X CHROMOSOME LINKED HYPERIMMUNOGLOBULIN M SYNDROME;

EID: 80053627848     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-351254     Document Type: Article

References (44)

1. Notarangelo LD, Duse M, Ugazio AG. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev. 1992;3(2):101-121.
2. Korthäuer U, Graf D, Mages HW, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993;361(6412):539-541. (Pubitemid 23055615)
3. Aruffo A, Farrington M, Hollenbaugh D, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72(2):291-300. (Pubitemid 23044943)
4. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152-172.
5. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, De Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature. 1993;361(6412):541-543. (Pubitemid 23055616)
6. Bhushan A, Covey LR. CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes. Immunol Res. 2001;24(3):311-324. (Pubitemid 33064389)
7. Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine. 2003;82(6):373-384. (Pubitemid 37445041)
8. Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev. 2005;203:48-66. (Pubitemid 40179693)
9. Castigli E, Fuleihan R, Ramesh N, Tsitsikov E, Tsytsykova A, Geha RS. CD40 ligand/CD40 deficiency. Int Arch Allergy Immunol. 1995;107(1-3):37-39.
10. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180(4):1263-1272. (Pubitemid 24289600)
11. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184(2):747-752. (Pubitemid 26324129)
12. Aghamohammadi A, Parvaneh N, Rezaei N, et al. Clinical and laboratory findings in hyper-IgM syndrome with novel CD40L and AICDA mutations. J Clin Immunol. 2009;29(6):769-776.
13. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1 Pt 1):47-54. (Pubitemid 27498308)
14. Hayward AR, Levy J, Facchetti F, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol. 1997;158(2):977-983. (Pubitemid 127492679)
15. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature. 1995;378(6557):617-620.
16. Bayrakci B, Ersoy F, Sanal O, Kilic S, Metin A, Tezcan I. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk J Pediatr. 2005;47(3):239-246. (Pubitemid 41535820)
17. Schneider LC. X-linked hyper IgM syndrome. Clin Rev Allergy Immunol. 2000;19(2):205-215.
18. Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant. 2008;42 Suppl 1:S49-S52.
19. Isam H, Al-Wahadneh A. Successful Bone Marrow Transplantation in a Child with X-Linked Hyper-IgM Syndrome. Saudi J Kidney Dis Transpl. 2004;15(4):489-493. (Pubitemid 40008290)
20. Barton-Burke M, Dwinell DM, Kafkas L, et al. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant. Oncology (Williston Park). 2008;22(11 Suppl Nurse Ed):31-45.
21. Hołowiecki J. Indications for hematopoietic stem cell transplantation. Pol Arch Med Wewn. 2008;118(11):658-663.
22. Kehry MR, Castle BE. Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation. Semin Immunol. 1994;6(5):287-294. (Pubitemid 124001526)
23. Barr TA, Carlring J, Heath AW. Co-stimulatory agonists as immunological adjuvants. Vaccine. 2006;24(17):3399-3407.
24. Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest. 1999;103(8):1151-1158. (Pubitemid 29207249)
25. Fuss IJ, Kanof ME, Smith PD, Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol. 2009; Chapter 7:Unit 7.1.
26. Rich RR, Mollick JA, Cook RG. Superantigens: interaction of staphylococcal enterotoxins with MHC class II molecules. Trans Am Clin Climatol Assoc. 1990;101:195-204, discussion 204-196.
27. Foster B, Prussin C, Liu F, Whitmire JK, Whitton JL. Detection of intracellular cytokines by flow cytometry. Curr Protoc Immunol. 2007;Chapter 6:Unit 6.24.
28. Jain A, Ma CA, Lopez-Granados E, et al. Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation. J Clin Invest. 2004;114(11):1593-1602. (Pubitemid 40385550)
29. Renshaw BR, Fanslow WC, 3rd Armitage RJ, et al. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med. 1994;180(5):1889-1900. (Pubitemid 24328578)
30. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 1996;273(5283):1862-1864. (Pubitemid 26322496)
31. Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19(13):3280-3287. (Pubitemid 32591446)
32. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions-new concepts. Clin Exp Allergy. 2007;37(7):989-999. (Pubitemid 46955519)
33. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol. 2006;118(4):949-956. (Pubitemid 44498760)
34. Notarangelo LD, Hayward AR. X-linked immunodeficiency with hyper-IgM (XHIM). Clin Exp Immunol. 2000;120(3):399-405. (Pubitemid 30365542)
35. Stewart AK, Huang C, Stollar BD, Schwartz RS. High-frequency representation of a single VH gene in the expressed human B cell repertoire. J Exp Med. 1993;177(4):1227.
36. Ochs HD, Hollenbaugh D, Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin Immunol. 1994;6(5):337-341. (Pubitemid 124001531)
37. Koch F, Stanzl U, Jennewein P, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med. 1996;184(2):741-746. (Pubitemid 26324128)
38. Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol. 2000;19(2):183-204.
39. Ochs HD, Smith CI. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine. 1996;75(6):287-299. (Pubitemid 27009232)
40. Quartier P, Bustamante J, Sanal O, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency. Clin Immunol. 2004;110(1):22-29. (Pubitemid 38177417)
41. Zhu Y, Nonoyama S, Morio T, Muramatsu M, Honjo T, Mizutani S. Type two hyper-IgM syndrome caused by mutation in activation-induced cytidine deaminase. J Med Dent Sci. 2003;50(1):41-46. (Pubitemid 41124454)
42. Brown MP, Topham DJ, Sangster MY, et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med. 1998;4(11):1253-1260. (Pubitemid 28512105)
43. Sacco MG, Ungari M, Cato EM, et al. Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome. Cancer Gene Ther. 2000;7(10):1299-1306.
44. Gennery AR, Khawaja K, Veys P, et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood. 2004;103(3):1152-1157. (Pubitemid 38129585)